Copper (64Cu) oxodotreotide
|Other names||Copper Cu 64 dotatate|
|Drug class||Radioactive diagnostic agent|
|Main uses||Positron emission tomography (PET) of neuroendocrine tumors (NETs)|
|Side effects||Nausea, vomiting, flushing|
|Chemical and physical data|
|Molar mass||1497.16 g·mol−1|
|3D model (JSmol)|
Copper (64Cu) oxodotreotide, sold under the brand name Detectnet, is a radioactive diagnostic agent used in positron emission tomography (PET) of neuroendocrine tumors (NETs). Specifically it is used in adults with somatostatin receptor positive disease. It is given by injection into a vein.
Common side effects include nausea, vomiting, and flushing. Other side effects include radiation exposure and allergic reactions. It interacts with somatostatin analogs. Use during pregnancy may harm the baby. It works by binding to somatostatin receptor, particularly subtype 2 receptors.
It is typically used at a dose of 148 MBq (4 mCi).
Trial 1 evaluated adults, some of whom had known or suspected NETs and some of whom were healthy volunteers. The trial was conducted at one site in the United States (Houston, TX). Both groups received copper 64Cu dotatate and underwent PET scan imaging.
Trial 2 data came from the literature-reported trial of 112 adults, all of whom had history of NETs and underwent PET scan imaging with copper 64Cu dotatate. The trial was conducted at one site in Denmark. In both trials, copper 64Cu dotatate images were compared to either biopsy results or other images taken by different techniques to detect the sites of a tumor. The images were read as either positive or negative for presence of NETs by three independent image readers who did not know participant clinical information.
- "Detectnet- copper cu 64 dotatate injection, solution". DailyMed. 14 September 2020. Archived from the original on 1 November 2022. Retrieved 24 September 2020.
- "Detectnet Prices, Coupons, Copay & Patient Assistance". Drugs.com. Archived from the original on 22 May 2022. Retrieved 3 November 2022.
- "Drug Trials Snapshots: Detectnet". U.S. Food and Drug Administration (FDA). 3 September 2020. Archived from the original on 21 September 2020. Retrieved 10 September 2020. This article incorporates text from this source, which is in the public domain.
- "Copper dotatate Cu-64". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2022-05-21. Retrieved 2022-10-20.
- "copper Cu 64 dotatate injection safety data sheet" (PDF). Curium US LLC. 15 March 2020. Archived (PDF) from the original on 27 October 2020. Retrieved 20 October 2022.